Tizanidine Hydrochloride Capsule
Product Images NDC 72888-002

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 72888-002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advagen Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (2 mg 150 Capsules Bottle)

Advagen Pharma Limited distributes a medicine called Tizanidine Hydrochloride in the form of 2mg capsules under the brand name Zanaflex. The package insert should be consulted for prescribing information. The medicine should be kept at a controlled room temperature of 25°C (77°F) with some excursions allowed to 15-30°C (59-86°F). Containers with child-resistant closures should be used when dispensing the medication, and it should be kept out of reach of children. The medicine is manufactured by Rubicon Research Private Limited in India, and the NDG 72888-001-15 lot number is interchangeable with tizanidine tablets or Zanaflex tablets.*

FDA Label Image

Principal Display Panel (4 mg 150 Capsule Bottle)

This is a medication label for capsules containing 4 mg tizanidine base, distributed by Advagen Pharma Limited. The capsules should be stored at room temperature and kept out of reach of children. The text also includes manufacturer information and prescribing instructions. The medication is not interchangeable with Zanaflex.*

FDA Label Image

Principal Display Panel (6 mg 150 Capsule Bottle)

FDA Label Image

Figure 1 (Tizanidine Hydrochloride Capsules Figure 1)

FDA Label Image

Figure 2 (Tizanidine Hydrochloride Capsules Figure 2)

This document is a chart or graph showing the improvement in Ashworth Score over a period of time measured in hours post-dose for two dosages of tizanidine - 16mg and 8mg.*

FDA Label Image

Figure 3 (Tizanidine Hydrochloride Capsules Figure 3)

The text describes a study on Tizanidine with a mean dose of 28.8mg in comparison to a placebo. The study measured the improvement in Ashworth Score and had three different time points, including the end of titration, the end of maintenance, and the endpoint. It is not mentioned what the results of the study were.*

FDA Label Image

Chemical Structural Formula (Tizanidine Hydrochloride Capsules Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.